Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$26.12 - $34.07 $714,120 - $931,473
-27,340 Reduced 19.36%
113,883 $3.88 Million
Q1 2024

May 14, 2024

SELL
$26.64 - $40.31 $2.36 Million - $3.58 Million
-88,701 Reduced 38.58%
141,223 $4.97 Million
Q4 2023

Feb 14, 2024

BUY
$19.95 - $31.0 $391,538 - $608,406
19,626 Added 9.33%
229,924 $6.64 Million
Q3 2023

Nov 13, 2023

SELL
$21.33 - $59.42 $24,529 - $68,333
-1,150 Reduced 0.54%
210,298 $4.82 Million
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $463,825 - $583,529
19,214 Added 10.0%
211,448 $5.66 Million
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $327,581 - $491,740
14,736 Added 8.3%
192,234 $5.44 Million
Q2 2022

Aug 12, 2022

SELL
$19.74 - $43.01 $3.01 Million - $6.57 Million
-152,729 Reduced 46.25%
177,498 $3.85 Million
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $755,558 - $1.08 Million
-20,843 Reduced 5.94%
330,227 $13.3 Million
Q4 2021

Feb 11, 2022

SELL
$43.27 - $65.72 $1.28 Million - $1.94 Million
-29,577 Reduced 7.77%
351,070 $16.6 Million
Q3 2021

Nov 12, 2021

SELL
$53.61 - $67.5 $2.29 Million - $2.89 Million
-42,767 Reduced 10.1%
380,647 $21.6 Million
Q2 2021

Aug 13, 2021

BUY
$45.13 - $64.99 $1.28 Million - $1.84 Million
28,375 Added 7.18%
423,414 $24.3 Million
Q1 2021

May 12, 2021

BUY
$29.77 - $84.85 $9.37 Million - $26.7 Million
314,764 Added 392.11%
395,039 $25 Million
Q4 2020

Feb 12, 2021

BUY
$25.66 - $34.55 $45,700 - $61,533
1,781 Added 2.27%
80,275 $2.69 Million
Q3 2020

Nov 12, 2020

BUY
$22.51 - $30.11 $543,188 - $726,584
24,131 Added 44.39%
78,494 $2.15 Million
Q2 2020

Aug 12, 2020

SELL
$12.65 - $29.57 $96,544 - $225,678
-7,632 Reduced 12.31%
54,363 $1.47 Million
Q1 2020

May 11, 2020

SELL
$10.84 - $20.85 $127,120 - $244,507
-11,727 Reduced 15.91%
61,995 $909,000
Q4 2019

Feb 14, 2020

BUY
$13.02 - $19.5 $959,860 - $1.44 Million
73,722 New
73,722 $1.27 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.